Your browser doesn't support javascript.
loading
Lubiprostone in the treatment of chronic idiopathic constipation: an update on health-related quality of life and patient-reported outcomes.
Hayat, Maham; Zia, Hassaan; Nusrat, Salman.
Afiliação
  • Hayat M; Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, maham-hayat@ouhsc.edu.
  • Zia H; Section of Digestive Diseases & Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Nusrat S; Section of Digestive Diseases & Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Patient Relat Outcome Meas ; 10: 43-47, 2019.
Article em En | MEDLINE | ID: mdl-30858742
ABSTRACT
Chronic idiopathic constipation, if inadequately treated, can be bothersome with a detrimental effect on patients' quality of life (QOL). This may also result in frequent health care visits, increasing the burden of this ailment's medical cost. Management strategies, focused on lifestyle changes, include increased exercise, a high-fiber diet, and toilet training. Pharmacologic options include fiber supplementation, laxatives, serotonergic agents, and prosecretory agents such as lubiprostone. In this review, we were able to conclude that lubiprostone, when used for chronic idiopathic constipation, has a significantly beneficial effect on both patients' symptoms and their QOL. In multiple randomized controlled trials, it has been found to have increased the number of spontaneous bowel movements at different time endpoints. Corresponding improvements were also observed for abdominal bloating, discomfort, stool frequency, and straining symptoms among patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2019 Tipo de documento: Article